Nano preparation for on-demand drug delivery for inherent barrier of pancreatic cancer and preparation method and application thereof
By developing a nanoformula, using PEG-pArg-pLys-Ni micelles to load STAT3 inhibitors and chemotherapy drugs, combined with hyaluronic acid coating, the matrix barrier and immunosuppression problems in PDAC treatment were solved, and the tumor site was achieved High-efficiency drug delivery and improved efficacy.
Patent Information
- Application Number
- CN202411099350.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Chemotherapy and immunotherapy for pancreatic ductal adenocarcinoma (PDAC) are poorly effective, mainly because the dense extracellular matrix and immunosuppressive barrier in the tumor microenvironment hinder the penetration of therapeutic drugs and the recruitment of immune cells.
Develop a nanoformula using polyethylene glycol-polyarginine-polylysine-nitroimidazole (PEG-pArg-pLys-Ni) as the basic unit for the construction of micelles, loading STAT3 inhibitor silybin and chemotherapeutic drug gemcitabine monophosphate, and coated by hyaluronic acid, use hydrophobic encapsulation and targeting functions to achieve on-demand release in the tumor microenvironment.
This nano-formula can stabilize circulation and enrich in tumor sites. By regulating STAT3 signal and releasing drugs, it reshapes the tumor microenvironment, enhances chemotherapy effects, improves anti-tumor efficacy, and reduces the risk of toxicity.
Smart Images

Figure CN118986933A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of pharmaceutical preparations, and relates to a nano preparation for releasing drugs on demand targeting the inherent barrier of pancreatic cancer, as well as a preparation method and application thereof. Background Art
[0002] Pancreatic ductal adenocarcinoma (PDAC) is extremely malignant. Clinically, radiotherapy and chemotherapy as conventional anti-tumor therapies or postoperative adjuvant therapies are crucial for the treatment of PDAC, but their overall efficacy is poor. At the same time, immunotherapy has achieved significant success in cancer treatment in recent years, but for PDAC patients, multiple clinical practices have shown that immunotherapy for anti-PDAC treatment is not effective.
[0003] Studies have shown that the PDAC tumor microenvironment is composed of cells and extracellular matrix components, and the inherent barrier that accounts for more than 80% of the volume is the main reason for its poor chemotherapy and immunotherapy effects. The collagen and fibrin secreted in large quantities by tumor-associated fibroblasts (CAFs) constitute a dense extracellular matrix (ECM), which continuously compresses the blood vessels of the tumor microenvironment to cause high interstitial fluid pressure and vascular malformations in the tumor, hindering the vascular penetration and tumor accumulation of therapeutic drugs, causing drug resistance, which is called the matrix physical barrier. At the same time, dense ECM and some cytokines also hinder the tumor recruitment and infiltration of killer immune cells such as adaptive immune cells (such as cytotoxic T cells) and NK cells, ultimately forming an immunosuppressive barrier, resulting in poor efficacy of emerging immunotherapies for PDAC.
[0004] In view of the inherent barrier characteristics of PDAC, various existing strategies for direct ECM ablation have not significantly improved patient survival, but have promoted the metastasis of PDAC to a certain extent. This shows that ECM has a contradictory dual role in the progression of PDAC: it is not only a drug-resistant barrier that affects the efficacy of drug treatment, but also a protective barrier that limits the migration and invasion of tumor cells. This dilemma challenges the strategy of eliminating ECM from the outside, and proposes the need for a drug delivery system for the treatment of PDAC based on the pathological characteristics of PDAC: improving the inherent barrier of PDAC without destroying the ECM, and synergizing the administration of chemotherapy drugs to penetrate the inherent barrier for anti-tumor treatment.
[0005] Smart drug delivery systems have excellent properties such as multi-module, modularity, integrity, and responsiveness, which are as follows: (1) they can achieve efficient and stable drug loading through covalent bonding, hydrophobic interaction, or electrostatic interaction; (2) they can increase the affinity of target cell surface molecules through targeted functional group modification, thereby achieving targeted uptake and accumulation of tumor cells; (3) they can respond to microenvironmental characteristics such as low pH, high ROS and GSH, and hypoxia in the tumor microenvironment, and rapidly release drugs to achieve tumor-specific and efficient inhibition of target receptors. Therefore, drug co-delivery schemes based on smart drug delivery systems may be an effective strategy for on-demand drug delivery against the inherent barrier of pancreatic cancer. Summary of the invention
[0006] In order to achieve the above-mentioned purpose, the present invention provides a method for preparing and applying a nanoformulation capable of releasing drugs on demand, regulating the intrinsic barrier of PDAC and performing anti-tumor treatment for the intrinsic barrier of pancreatic cancer. The present invention selects polyethylene glycol-polyarginine-polylysine-nitroimidazole (PEG-pArg-pLys-Ni, PAL-Ni) as the basic unit for constructing micelles. The polymer fragment can adsorb gemcitabine monophosphate, which is the activated form of the chemotherapy drug gemcitabine, through the positive charge of polyarginine.
[0007] Signal transducer and activator of transcription 3 (STAT3) molecules play a key role in the progression of PDAC. Activation of the STAT3 pathway can promote the proliferation and metastasis of tumor cells, mediate the formation of ECM by pancreatic stromal cells, and participate in the construction of an immunosuppressive microenvironment. Therefore, extensively inhibiting the phosphorylation of STAT3 molecules in the tumor microenvironment, enhancing the ability of chemotherapeutic drugs to induce cell apoptosis, and reshaping the ECM and immune environment are effective means to regulate the inherent barrier of PDAC.
[0008] The micelle can load STAT3 inhibitor silybin by hydrophobic encapsulation. In order to improve the circulation stability and tumor accumulation ability of the micelle, hyaluronic acid is coated on the surface of the micelle to obtain a hyaluronic acid-coated drug-loaded nanoformulation.
[0009] The electronegatively charged nanoformulation circulates stably in the body. When it reaches the tumor site, the hyaluronic acid on its surface can bind to the CD44 molecules on the surface of the tumor cells, achieving the enrichment of nanoparticles in the tumor area and turning the surface charge of the micelle positive. When the positively charged micelle is in the hypoxic area of the tumor, the hydrophobic nitroimidazole group in the polymer fragment will be reduced to a hydrophilic group by nitroimidazole reductase, promoting the disintegration of the micelle. At this time, silybin is released in the tumor microenvironment and widely regulates STAT3 signals, regulating the inherent barrier of PDAC, while gemcitabine monophosphate is attached to the positively charged polymer fragment to penetrate deep into the tumor to kill tumor cells.
[0010] Specifically, the present invention relates to a nanoformulation for on-demand drug release targeting the inherent barrier of pancreatic cancer, and more particularly to an intelligent nano-drug delivery system that can penetrate the dense matrix of the tumor, achieve chemotherapy sensitization, reshape the ECM, and reverse the immunosuppressive microenvironment, thereby improving the anti-tumor efficacy of PDAC.
[0011] To achieve the above purpose, the technical solution provided by the present invention is as follows:
[0012] The present invention provides a nano preparation for on-demand drug release targeting the inherent barrier of pancreatic cancer, which is composed of micelles prepared from polymer PEG-pArg-pLys-Ni with a simplified structural formula as shown in Formula I, entrapped silybin, electrostatically adsorbed gemcitabine monophosphate and coated with hyaluronic acid.
[0013]
[0014] Preferably, HPLC measured that the drug loading of gemcitabine monophosphate in the nanoformulation was 4.7%, and the drug loading of silibinin was 8.6%; the average particle size of the nanoformulation was 59.19±1.63 nm, and the Zeta potential was -10.77±0.37 mV.
[0015] In the present invention, the ratio of the number of repeating units of the polyethylene glycol segment, the polyarginine segment and the polylysine segment in the PEG-pArg-pLys-Ni is 1:11:21 as determined by hydrogen nuclear magnetic resonance spectroscopy.
[0016] The present invention also provides a method for preparing the above-mentioned nanoformulation, comprising the following steps:
[0017] The polymer PEG-pArg-pLys-Ni and silybin are dispersed in an organic solvent by a thin film hydration method, the organic solvent is removed by rotary evaporation to form a thin film, ultrapure water is added and ultrasonic dispersion is performed to obtain micelles, the micelles are mixed and adsorbed with gemcitabine monophosphate, and then mixed with hyaluronic acid for coating, and after coating, the unencapsulated free drug is removed by dialyzation to obtain a nano preparation.
[0018] Preferably, the mass ratio of PEG-pArg-pLys-Ni to silybin, gemcitabine monophosphate and hyaluronic acid is 8:1:8:4; the organic solvent is DMF; the mass ratio of ultrapure water to PEG-pArg-pLys-Ni is 2000:1; the ultrasonic dispersion time is 2h; the mixing time of micelles and gemcitabine monophosphate is 1h; and the hyaluronic acid coating time is 2h.
[0019] The present invention also provides a method for preparing the polymer PEG-pArg-pLys-Ni having the structural formula shown in Formula I, comprising the following steps:
[0020] (1) N6 -Benzyloxycarbonyl-L-lysine and triphosgene were used to synthesize Lys(Cbz)-NCA according to the Fuchs-farthing method, and the reaction temperature was 50°C; the reaction formula is shown in Formula II:
[0021]
[0022] (2) Boc-ornithine and triphosgene are used to synthesize Orn(Boc)-NCA according to the Fuchs-farthing method, and the reaction temperature is 50° C. The reaction formula is shown in Formula III:
[0023]
[0024] (3) The Lys(Cbz)-NCA obtained in step (1) and the Orn(Boc)-NCA obtained in step (2) are subjected to a ring-opening polymerization reaction with polyethylene glycol at 40-60° C. under anaerobic conditions to obtain PEG-pOrn(Boc)-pLys(Cbz); the reaction formula is shown in Formula IV:
[0025]
[0026] (4) removing the Boc protecting group from the PEG-pOrn(Boc)-pLys(Cbz) obtained in step (3) in an ice bath in trifluoroacetic acid, as shown in Formula V; and adding a guanidinating agent to an aqueous solution under alkaline conditions to carry out a guanidinating reaction to obtain a white solid PEG-pArg-pLys(Cbz); the reaction formula is shown in Formula VI:
[0027]
[0028] (5) removing the Cbz protecting group from the PEG-pArg-pLys(Cbz) obtained in step (4) in a trifluoroacetic acid / hydrobromic acid / acetic acid environment to obtain PEG-pArg-pLys. The reaction formula is shown in Formula VII.
[0029]
[0030] (6) 2-hydroxymethyl-1-methyl-5-nitroimidazole is mixed with an acid binding agent, a catalyst, and p-nitrophenyl chloroformate and reacted at room temperature to obtain a white solid PNP-Ni. The reaction formula is shown in Formula VIII.
[0031]
[0032] (7) taking the PNP-Ni in step (6) and the PEG-pArg-pLys in step (5) and reacting them with an acid binding agent and a catalyst at room temperature to obtain PEG-pArg-pLys-Ni, the reaction formula is shown in Formula IX;
[0033]
[0034] Preferably, in step (1), N 6 The molar ratio of -benzyloxycarbonyl-L-lysine to triphosgene is 2.5:1; the specific steps of step (1) are: 6 -Benzyloxycarbonyl-L-lysine and triphosgene were added to the reaction flask and argon was passed through for protection; anhydrous tetrahydrofuran was added as a solvent while stirring, and the reaction was carried out at 50°C for 2 hours. After the reaction was completed, the temperature of the reaction liquid was restored to room temperature; the reaction liquid was dripped into n-hexane precooled at -20°C while stirring; a white solid was obtained by suction filtration, namely Lys(Cbz)-NCA.
[0035] Preferably, in step (2), Boc-ornithine and triphosgene are used to synthesize Orn(Boc)-NCA according to the Fuchs-farthing method, and the molar ratio of Boc-ornithine to triphosgene is 2.5:1; the specific steps of step (2) are: adding Boc-ornithine and triphosgene to a reaction bottle, and passing argon gas for protection; stirring and adding anhydrous tetrahydrofuran as a solvent, reacting at 50°C for 0.5-1h, and after the reaction is completed, returning the temperature of the reaction liquid to room temperature; while stirring, dripping the reaction liquid into -20°C pre-cooled n-hexane; and filtering to obtain Orn(Boc)-NCA.
[0036] Preferably, in step (3), the molar ratio of polyethylene glycol, Orn(Boc)-NCA, and Lys(Cbz)-NCA is 1:(10-13):(18-22), and the polyethylene glycol is CH 3 O-PEG-NH 2 , the number of repeating units is 112; the specific steps of step (3) are: CH 3 O-PEG-NH 2 Place in a reaction bottle, add Orn(Boc)-NCA, after argon protection, add solvent anhydrous DMF, react at 40-60°C for 48 hours; then add Lys(Cbz)-NCA, and continue to react for 48 hours; after the reaction is completed, transfer the reaction solution to a dialysis bag, dialyze in deionized water for 24 hours, and change the water twice; then freeze-dry the liquid in the dialysis bag to obtain a white solid PEG-pOrn(Boc)-pLys(Cbz).
[0037] Preferably, the molar ratio of PEG-pOrn(Boc)-pLys(Cbz) to the guanidinating agent in step (4) is 1:20; the guanidinating agent is 3,5-dimethylpyrazole-1-carboxamidine nitrate, and the pH value of the alkaline condition is 9.3.
[0038] Further preferably, in step (4), the method for removing the Boc protecting group from PEG-pOrn(Boc)-pLys(Cbz) is as follows: 1.5 g of PEG-pOrn(Boc)-pLys(Cbz) is added to 40 mL of a mixed solvent of DCM and TFA, wherein the volume ratio of DCM:TFA is 1:1, the mixture is stirred for reaction for 20 min under ice bath, and the solvent is removed by vacuum rotary evaporation; the specific steps of the guanidination reaction described in step (4) are as follows: 0.476 g of 3,5-dimethylpyrazole-1-carboxamidine nitrate and 90 mL of water are added, the pH of the reaction system is adjusted to 9.3 with NaOH solution, and then the reaction is carried out at 37° C. for 48 h, and then the reaction solution is transferred to a dialysis bag, dialyzed in deionized water for 48 h, the water is changed four times, and freeze-dried to obtain a white solid PEG-pArg-pLys(Cbz).
[0039] Preferably, in step (5), 1 g of PEG-pArg-pLys (Cbz) is added to a mixed solution of 40 mL of TFA and 2 mL of hydrobromic acid / acetic acid (HBr / HOAc, 33%, v / v) under ice bath conditions, and after reacting for 3 h under ice bath, dialyzed in deionized water for 24 h, changing the water four times; and then freeze-dried to obtain a white solid PEG-pArg-pLys.
[0040] Preferably, the acid binding agent in step (6) and step (7) is triethylamine, and the catalyst is 4-dimethylaminopyridine.
[0041] Further preferably, in step (6), the molar ratio of 2-hydroxymethyl-1-methyl-5-nitroimidazole to triethylamine, 4-dimethylaminopyridine, and p-nitrophenyl chloroformate is 1:(1.3-1.5):(0.005-0.02):(1.3-1.8); the specific steps of step (6) are: dissolving 2-hydroxymethyl-1-methyl-5-nitroimidazole, triethylamine and 4-dimethylaminopyridine in anhydrous THF to obtain a mixed solution; slowly adding a tetrahydrofuran solution of p-nitrophenyl chloroformate dropwise to the mixed solution within 2 hours; then reacting at room temperature for 10 hours; after the reaction is completed, adding silica gel powder, removing the solvent by vacuum rotary evaporation, and purifying by column chromatography to obtain a white solid PNP-Ni, wherein the mobile phase of the column chromatography is a petroleum ether / ethyl acetate mixture with a volume ratio of (4-1):1.
[0042] Further preferably, in step (7), the molar ratio of PEG-pArg-pLys to triethylamine, 4-dimethylaminopyridine, and PNP-Ni is 1:(20-25):(0.1-0.3):(20-22); the specific steps of step (7) are: PEG-pArg-pLys, Et 3N, DMAP and PNP-Ni were dissolved in DMF to obtain a reaction solution, which was stirred at room temperature for 12 h and then transferred to a dialysis bag, dialyzed in DMF for 24 h, with the DMF changed once, and then dialyzed in deionized water for 24 h, with the water changed twice, and freeze-dried to obtain a green solid PEG-pArg-pLys-Ni.
[0043] The present invention also provides the use of the nano preparation in preparing anti-pancreatic cancer drugs.
[0044] Compared with the prior art, the present invention has the following beneficial effects:
[0045] (1) The nanoformulation described in the present invention can circulate stably and for a long time in the body, has obvious solid tumor accumulation ability, and can effectively deliver drugs to the tumor site.
[0046] (2) The polymer fragment in the present invention uses polyethylene glycol, amino acids, and nitroimidazole as the skeleton, and combines silybin, which is low in toxicity to the human body, with hyaluronic acid, which has good biocompatibility, to construct a delivery system, thereby reducing the risk of systemic toxicity introduced by nanocarriers.
[0047] (3) The nanoformulation described in the present invention can respond to the hypoxic conditions in the tumor microenvironment, release STAT3 inhibitors in the tumor microenvironment as needed, deliver chemotherapy drugs to the deep layers of the tumor, and achieve chemotherapy sensitization, tumor matrix remodeling, and reversal of the immune microenvironment through multi-target joint regulation, thereby improving the anti-tumor efficacy. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Figure 1 This is the synthetic route of the polymer PEG-pArg-pLys-Ni.
[0049] Figure 2 is the H NMR spectrum of the polymer PEG-pArg-pLys-Ni ( 1 H NMR) spectrum.
[0050] Figure 3 The particle size (a) and microscopic morphology (b) of the nanoformulation described in Example 1 of the present invention.
[0051] Figure 4 The hypoxic reduction condition response characteristics of the nanoformulation described in Example 1 of the present invention; 2 S 2 O 4 After incubation, a) particle size distribution determined by DLS, b) TEM image; c) release kinetics of encapsulated drugs.
[0052] Figure 5 This is an investigation of the tumor penetration ability of the nanoformulation of Example 1 of the present invention in the Pan02 tumor sphere model.
[0053] Figure 6 This is the regulation of the expression of pSTAT3 and Bcl-2 proteins in the Pan02 cell line under normoxic and hypoxic conditions by the nanoformulation of Example 1 of the present invention.
[0054] Figure 7 These are the results of the in vivo distribution investigation of the nanoformulation of Example 1 of the present invention in mice bearing Pan02 orthotopic pancreatic cancer; wherein, a) the in vivo distribution results of the polymer fragment fluorescence signals of each mouse, b) the distribution results of the polymer fragment fluorescence signals in each organ, and c) the quantitative results of b.
[0055] Figure 8 The anti-tumor efficacy of the nano-preparation of Example 1 of the present invention in mice bearing Pan02 orthotopic pancreatic cancer and the weight changes of each group; wherein, a) a graph showing the changes in tumor bioluminescence signals of each group of mice over time, b) a graph showing the survival curves of each group of mice, and c) a graph showing the weight changes of each group of mice. DETAILED DESCRIPTION
[0056] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, the embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.
[0057] Example 1
[0058] A nanoformulation for on-demand drug release targeting the inherent barrier of pancreatic cancer, comprising micelles prepared from a polymer PEG-pArg-pLys-Ni having a structural formula as shown in Formula I, encapsulating silibinin, electrostatically adsorbing gemcitabine monophosphate and coating hyaluronic acid; HPLC measurement showed that the drug loading of the nanoformulation for gemcitabine monophosphate was 4.7%, and the drug loading of silibinin was 8.6%; the average particle size of the nanoformulation was 59.19±1.63nm, and the Zeta potential was -10.77±0.37mV.
[0059] The overall synthetic route of the polymer fragment PEG-pArg-pLys-Ni is as follows: Figure 1 As shown, the following steps are included:
[0060] 1) Weigh 1g N 6-Benzyloxycarbonyl-L-lysine and 0.423g triphosgene were placed in a 50mL two-necked bottle, replaced with argon protection, stirred and added with 50mL anhydrous tetrahydrofuran as solvent, and reacted at 50°C for 2h. The reaction process is as shown in Formula II. After the reaction, the temperature was restored to room temperature, and the solution was clear. The reaction solution was dripped into -20°C pre-cooled n-hexane while stirring, and the filter cake was filtered to obtain a white solid, which was Lys(Cbz)-NCA.
[0061] 2) Weigh 1g N 6 -tert-Butyloxycarbonyl-L-ornithine and 0.459g triphosgene were placed in a 50mL two-necked bottle, replaced with argon protection, stirred and added with 50mL anhydrous tetrahydrofuran as solvent, and reacted at 50°C for 0.5h. The reaction process is as shown in Formula III. The reaction was stopped immediately after the solution became clear. The insoluble matter was removed by filtration. The reaction solution was dripped into n-hexane precooled at -20°C while stirring. The filter cake was obtained by suction filtration, and the product was white solid Orn(Boc)-NCA.
[0062] 3) Prepare the polymer PEG-pOrn(Boc)-pLys(Cbz) by NCA ring-opening polymerization, the reaction process is as shown in Formula IV. 3 O-PEG-NH 2 Place in a 50mL two-necked bottle, add 0.342g Orn(Boc)-NCA, replace with argon protection, add 15mL anhydrous DMF as solvent, react at 50°C for 48h, and the solution can be observed to be clear. Then add 0.651g Lys(Cbz)-NCA and continue to react at the temperature for 48h. After the reaction is completed, transfer the reaction solution to a dialysis bag (MW=3500), dialyze in deionized water for 24h, and change the water twice. Then freeze-dry the liquid in the dialysis bag to obtain a white solid PEG-pOrn(Boc)-pLys(Cbz).
[0063] 4) First remove the Boc protecting group of ornithine in the polymer, and the reaction process is as shown in Formula V. Add 1.5g of PEG-pOrn(Boc)-pLys(Cbz) to 40mL of DCM / TFA mixed solvent with a volume ratio of 1:1, and stir and react for 20min under ice bath. Then remove the solvent by vacuum rotary evaporation. Then the deprotected product is guanidinized again, and the reaction process is as shown in Formula VI. Add 0.476g of 3,5-dimethylpyrazole-1-carboxamidine nitrate and 90mL of water to the reaction solution, adjust the pH of the reaction system to 9.3 with NaOH solution, and react at 37°C for 48h, then transfer the reaction solution to a dialysis bag, dialyze in deionized water for 48h, change the water four times, and freeze-dry to obtain a white solid PEG-pArg-pLys(Cbz).
[0064] 5) 1 g of PEG-pArg-pLys (Cbz) was added to a mixed solution of 40 mL of TFA and 2 mL of hydrobromic acid / acetic acid (HBr / HOAc, 33%) in an ice bath, and reacted for 3 h in an ice bath, and then dialyzed in deionized water for 24 h, changing the water four times. Then, PEG-pArg-pLys was obtained by freeze drying. The reaction process is shown in Formula VII.
[0065] 6) Prepare the intermediate PNP-Ni of polymerized Ni, and the reaction process is shown in Formula VII. Dissolve 905.4 mg of 2-hydroxymethyl-1-methyl-5-nitroimidazole, 559.2 mg of triethylamine and 10 mg of 4-dimethylaminopyridine in 80 mL of anhydrous THF to obtain a mixed solution; slowly add the solution obtained by dissolving 1747.4 mg of p-nitrophenyl chloroformate in 20 mL of anhydrous tetrahydrofuran to the mixed solution within 2 hours. Then react at room temperature for 10 hours. After the reaction, add silica gel powder, remove the solvent by vacuum rotary evaporation, and purify by column chromatography to obtain a white solid PNP-NI. The mobile phase used in the column chromatography is petroleum ether / ethyl acetate with a volume ratio of 4-1:1.
[0066] 7) Prepare the polymer fragment PEG-pArg-pLys-Ni for micelle preparation. The reaction process is shown in Formula IX. Weigh 1.5 g of PEG-pArg-pLys, 336.5 mg of Et 3 N, 2 mg of DMAP and 968.8 mg of PNP-NI were dissolved in DMF and stirred at room temperature for 12 h. The reaction solution was then transferred to a dialysis bag and dialyzed in DMF for 24 h, with DMF changed once. It was then dialyzed in deionized water for 24 h, with water changed twice. After freeze drying, a green solid PEG-pArg-pLys-Ni was obtained. The results of its H NMR spectrum are as follows: Figure 2 shown.
[0067] The method for preparing a nanoformulation for on-demand drug release targeting the inherent barrier of pancreatic cancer comprises the following steps:
[0068] 10 mg of polymer PEG-pArg-pLys-Ni and 1.3 mg of silybin were dispersed in 2 mL of DMF, and the DMF was removed by oil pump evaporation to form a thin film. 20 mL of ultrapure water was added and ultrasonic dispersion was performed for 2 h to obtain micelles, which were mixed with 10 mg of gemcitabine monophosphate and stirred for adsorption for 1 h. The micelles were mixed with 5 mg of hyaluronic acid and stirred for 2 h for coating. The micelles were dialyzed in deionized water for 24 h to remove the unencapsulated free drugs and obtain the nanoformulation.
[0069] The particle size and distribution of nanoparticles, microscopic morphology, etc. Figure 3 As shown. Figure 3 It can be seen that the average particle size of the nanoparticle preparation is 59.19±1.63nm, and the polydispersity coefficient is 0.059 ( Figure 3 a), uniform and rounded appearance ( Figure 3 b).
[0070] The nanoformulation was analyzed for its response characteristics under hypoxic reduction conditions. Figure 4 shown.
[0071] The a figure is with Na 2 S 2 O 4 The particle size distribution diagram determined by DLS after incubation shows from Figure a that under strong reducing conditions, the size distribution of nanoparticles shows a significant increasing trend and the distribution uniformity decreases.
[0072] Figure b shows the relationship between Na 2 S 2 O 4 The TEM image after incubation shows that under strong reducing conditions, the uniform round structure of the nanoparticles changes, indicating that their micelle structure collapses.
[0073] Figure c is a study on the release kinetics of the encapsulated drug. It can be seen from Figure c that under simulated anaerobic reducing conditions, the encapsulated drug can be released by 80% within 24 hours, while under normoxic conditions, less than 40% is released.
[0074] The tumor penetration ability of the nanoparticles was investigated in the Pan02 tumor sphere model. Figure 5 As shown in the figure. Under hypoxic conditions, the micellar polymer fragments have stronger tumor tissue penetration, proving that their structure collapses at the cellular level in response to hypoxia, promoting the penetration of the fragments. The penetration is further enhanced after hyaluronidase treatment, indicating that the hyaluronic acid on the surface of the nanoformulation can be further promoted by flipping it to positive charge after shedding, which can further promote its penetration.
[0075] The regulation of the nanoparticles on the expression of pSTAT3 and Bcl-2 proteins in Pan02 cell lines under normoxic and hypoxic conditions was investigated. Figure 6 As shown: Under normal and hypoxic conditions, low-dose nanoformulations have a significant downregulation effect on pSTAT3, while high-dose nanoformulations have a stronger downregulation effect on Bcl-2. Bcl-2 is a key molecule in the anti-apoptotic pathway of tumor cells, indicating that this nanoformulation can achieve chemotherapy sensitization by acting on the STAT3 pathway.
[0076] The in vivo distribution of the nanoformulation in mice bearing Pan02 orthotopic pancreatic cancer was investigated. Figure 7As shown. First, the polymer fragment PEG-pArg-pLys-Ni was fluorescently labeled with Cy5. The specific steps were as follows: 10 mg (0.001 mmol) of PEG-pArg-pLys-Ni and 2.9 mg (0.001 mmol) of Cy5-NHS probe were weighed and dissolved in a small amount of DMSO. After stirring at room temperature for 6 hours in the dark, the material PAL-Ni-Cy5 was obtained by dialyzing and freeze-drying. The Cy5-labeled nanocarrier was prepared by mixing PAL-Ni-Cy5 and PAL-Ni in a ratio of 1:9. Then, a Pan02-loaded in situ PDAC mouse model was constructed. Pan02-Luci cells were cultured under standard conditions. After the cell confluence was above 70%, the cells were resuspended in HBSS to a concentration of 2.0×10 6 / 100μL. After the male C57BL / 6 mice were completely anesthetized, the hair of the pancreas was shaved and the left upper abdomen was cut open to expose the pancreas. 50μL of the cell suspension was injected in situ into the pancreatic tissue, and the model was sutured surgically to complete the construction. A total of 100μL of nanoformulations containing a Cy5 concentration of 300ng / 100μL or micelles without hyaluronic acid were injected into the mice through the tail vein. The signal distribution of Cy5 in mice was monitored using the small animal in vivo imaging system (IVIS) at 1h, 4h, 12h, and 24h. After 24h of drug administration and signal monitoring, the mice were killed and perfused with saline. The heart, liver, spleen, lung, kidney and tumor tissues were removed, and the signal distribution was observed using IVIS.
[0077] Figure a shows the distribution of fluorescence signals of each mouse in vivo. The results show that the nanoformulation coated with hyaluronic acid has a longer in vivo circulation than the positively charged micelles.
[0078] Figures b and c show the distribution results of the fluorescence signals of polymer fragments in various organs of mice, which indicate that the nanoformulation has a better tumor accumulation effect than the positively charged micelles, and is less distributed in the liver organ, with good targeting.
[0079] The anti-tumor effect of the nanoformulation was investigated by intravenous administration of the nanoformulation to mice bearing Pan02 orthotopic pancreatic cancer every 2 days for a total of 5 times over 12 days. Figure 8 The preparations administered to mice in each group were G1: normal saline; G2: gemcitabine (5 mg / kg); G3: gemcitabine (5 mg / kg) and silybin free drug (10 mg / kg); G4: positively charged micelles without hyaluronic acid coating; G5: the nanoformulation described in the present invention.
[0080] Figure a is a graph of the bioluminescent signal of the tumor in mice. The results show that the G5 nanoformulation group has the best effect in inhibiting tumor growth.
[0081] Figure b is the survival curve of mice. The results show that the survival rate of mice in the G5 nanoformulation group was the highest and it had good anti-tumor efficacy.
[0082] Figure c is the weight change curve of mice. There is no obvious change in weight of mice in each group, indicating that at this dose, the preparation has good biosafety in the body.
[0083] For the construction of polymers, if the conditions are not prepared according to the method described in this application, the target nanoformulation cannot be successfully prepared and its application is also limited.
[0084] Comparative Example 1
[0085] A nanoformulation, compared with Example 1, the difference is that the molar ratio of polyethylene glycol, Orn(Boc)-NCA, and Lys(Cbz)-NCA in step (3) is not in the range of 1:(10-13):(18-22), but is 1:17:20, and the Zeta potential of the final nanoformulation is -2.56mV. The nanoformulation with a potential of about -10.77mV described in the present application cannot be successfully prepared. The reason for the analysis is that the excessively high polyarginine fragment will result in a lower absolute value of the potential of the final nanoformulation, and it will not be able to maintain a stable negative charge in the systemic circulation.
[0086] Comparative Example 2
[0087] A nanoformulation, compared with Example 1, the difference is that in step (7), the molar ratio of PEG-pArg-pLys to triethylamine, 4-dimethylaminopyridine, and PNP-Ni is not within the range of 1:(20-25):(0.1-0.3):(20-22), but is 1:20:0.1:10, and the particle size of the nanoformulation finally obtained is 100.80nm. The nanoformulation with an average particle size of 59.19±1.63nm described in the present application cannot be successfully obtained. The reason for the analysis is that the polymer has insufficient hydrophobic segments to form a stable and uniform micelle structure.
Claims
1. A nanoformulation for on-demand drug release targeting the inherent barrier of pancreatic cancer, characterized in that: The micelles prepared by the polymer PEG-pArg-pLys-Ni with a simplified structural formula as shown in Formula I encapsulate silibinin, electrostatically adsorb gemcitabine monophosphate and are coated with hyaluronic acid; preferably, HPLC measured that the drug loading of the nanoformulation for gemcitabine monophosphate is 4.7%, and the drug loading of silibinin is 8.6%; the average particle size of the nanoformulation is 59.19±1.63nm, and the Zeta potential is -10.77±0.37mV; 2. The nanoformulation for on-demand drug release targeting the inherent barrier of pancreatic cancer according to claim 1, characterized in that: The preparation method of the polymer PEG-pArg-pLys-Ni having a simplified structural formula as shown in Formula I comprises the following steps: (1) N6-benzyloxycarbonyl-L-lysine and triphosgene were reacted by the Fuchs-farthing method to synthesize Lys(Cbz)-NCA at a reaction temperature of 50°C; the reaction formula is shown in Formula II: (2) Boc-ornithine and triphosgene are used to synthesize Orn(Boc)-NCA according to the Fuchs-farthing method, and the reaction temperature is 50° C. The reaction formula is shown in Formula III: (3) The Lys(Cbz)-NCA obtained in step (1) and the Orn(Boc)-NCA obtained in step (2) are subjected to a ring-opening polymerization reaction with polyethylene glycol at 40-60° C. under anaerobic conditions to obtain PEG-pOrn(Boc)-pLys(Cbz); the reaction formula is shown in Formula IV: (4) removing the Boc protecting group from the PEG-pOrn(Boc)-pLys(Cbz) obtained in step (3) in an ice bath in trifluoroacetic acid, as shown in Formula V; and adding a guanidinating agent to an aqueous solution under alkaline conditions to carry out a guanidinating reaction to obtain a white solid PEG-pArg-pLys(Cbz); the reaction formula is shown in Formula VI: (5) removing the Cbz protecting group from the PEG-pArg-pLys(Cbz) obtained in step (4) in a trifluoroacetic acid / hydrobromic acid / acetic acid environment to obtain PEG-pArg-pLys. The reaction formula is shown in Formula VII. (6) 2-hydroxymethyl-1-methyl-5-nitroimidazole is mixed with an acid binding agent, a catalyst, and p-nitrophenyl chloroformate, and reacted at room temperature to obtain a white solid PNP-Ni. The reaction formula is shown in Formula VIII; (7) taking the PNP-Ni in step (6) and the PEG-pArg-pLys in step (5) and reacting them with an acid binding agent and a catalyst at room temperature to obtain PEG-pArg-pLys-Ni, the reaction formula is shown in Formula IX; 3. The nanoformulation for on-demand drug release targeting the inherent barrier of pancreatic cancer according to claim 2, characterized in that: The molar ratio of N6-benzyloxycarbonyl-L-lysine to triphosgene in step (1) is 2.5:1; the specific steps of step (1) are: adding N6-benzyloxycarbonyl-L-lysine and triphosgene to a reaction bottle, and passing argon gas for protection; stirring and adding solvent anhydrous tetrahydrofuran, reacting at 50°C for 2h, and returning the reaction liquid temperature to room temperature after the reaction is completed; while stirring, dripping the reaction liquid into -20°C pre-cooled n-hexane; and filtering to obtain a white solid, namely Lys(Cbz)-NCA.
4. The nanoformulation for on-demand drug release targeting the inherent barrier of pancreatic cancer according to claim 2, characterized in that: In step (2), Boc-ornithine and triphosgene are used to synthesize Orn(Boc)-NCA according to the Fuchs-farthing method, and the reaction time is 0.5-1h; the molar ratio of Boc-ornithine to triphosgene is 2.5:1; the specific steps of step (2) are: adding Boc-ornithine and triphosgene to a reaction bottle, and passing argon gas for protection; stirring and adding solvent anhydrous tetrahydrofuran, reacting at 50°C for 2h, and after the reaction is completed, the temperature of the reaction liquid is restored to room temperature; while stirring, the reaction liquid is dripped into -20°C pre-cooled n-hexane; and filtering to obtain Orn(Boc)-NCA.
5. The nanoformulation for on-demand drug release targeting the inherent barrier of pancreatic cancer according to claim 2, characterized in that: In step (3), the molar ratio of polyethylene glycol, Orn(Boc)-NCA and Lys(Cbz)-NCA is 1:(10-13):(18-22), and the polyethylene glycol is CH3O-PEG-NH2, and the number of repeating units is 112; the specific steps of step (3) are: placing CH3O-PEG-NH2 in a reaction bottle, adding Orn(Boc)-NCA, after passing argon protection, adding solvent anhydrous DMF, and reacting at 40-60°C for 48 hours; then adding Lys(Cbz)-NCA and continuing the reaction for 48 hours; after the reaction is completed, transferring the reaction solution to a dialysis bag, dialyzing in deionized water for 24 hours, and changing the water twice; then freeze-drying the liquid in the dialysis bag to obtain a white solid PEG-pOrn(Boc)-pLys(Cbz).
6. The nanoformulation for on-demand drug release targeting the inherent barrier of pancreatic cancer according to claim 2, characterized in that: The molar ratio of PEG-pOrn(Boc)-pLys(Cbz) to the guanidinating agent in step (4) is 1:20; the guanidinating agent is 3,5-dimethylpyrazole-1-carboxamidine nitrate, and the pH value of the alkaline condition is 9.3; Preferably, in step (4), the method for removing the Boc protecting group from PEG-pOrn(Boc)-pLys(Cbz) is as follows: 1.5 g of PEG-pOrn(Boc)-pLys(Cbz) is added to 40 mL of a mixed solvent of DCM and TFA, wherein the volume ratio of DCM:TFA is 1:1, the mixture is stirred for reaction for 20 min under ice bath, and the solvent is removed by vacuum rotary evaporation; the specific steps of the guanidination reaction described in step (4) are as follows: 0.476 g of 3,5-dimethylpyrazole-1-carboxamidine nitrate and 90 mL of water are added, the pH of the reaction system is adjusted to 9.3 with NaOH solution, and then the reaction is carried out at 37° C. for 48 h, and then the reaction solution is transferred to a dialysis bag, dialyzed in deionized water for 48 h, the water is changed four times, and freeze-dried to obtain a white solid PEG-pArg-pLys(Cbz).
7. The nanoformulation for on-demand drug release targeting the inherent barrier of pancreatic cancer according to claim 2, characterized in that: In step (5), 1 g of PEG-pArg-pLys (Cbz) was added to a mixed solution of 40 mL of TFA and 2 mL of hydrobromic acid / acetic acid (HBr / HOAc, 33%, v / v) under ice bath conditions, and after reacting for 3 h under ice bath, dialyzed in deionized water for 24 h, changing the water four times; and then freeze-dried to obtain a white solid PEG-pArg-pLys.
8. The nanoformulation for on-demand drug release targeting the inherent barrier of pancreatic cancer according to claim 2, characterized in that: The acid binding agents in step (6) and step (7) are both triethylamine, and the catalysts are both 4-dimethylaminopyridine; Preferably, in step (6), the molar ratio of 2-hydroxymethyl-1-methyl-5-nitroimidazole to triethylamine, 4-dimethylaminopyridine, and p-nitrophenyl chloroformate is 1:(1.3-1.5):(0.005-0.02):(1.3-1.8); the specific steps of step (6) are: dissolving 2-hydroxymethyl-1-methyl-5-nitroimidazole, triethylamine and 4-dimethylaminopyridine in anhydrous THF to obtain a mixed solution; slowly adding a tetrahydrofuran solution of p-nitrophenyl chloroformate dropwise to the mixed solution within 2 hours; then reacting at room temperature for 10 hours; after the reaction is completed, adding silica gel powder, removing the solvent by vacuum rotary evaporation, and purifying by column chromatography to obtain a white solid PNP-Ni, wherein the mobile phase of the column chromatography is a petroleum ether / ethyl acetate mixture with a volume ratio of (4-1):1; Preferably, in step (7), the molar ratio of PEG-pArg-pLys to triethylamine, 4-dimethylaminopyridine, and PNP-Ni is 1:(20-25):(0.1-0.3):(20-22); the specific steps of step (7) are: dissolving PEG-pArg-pLys, Et3N, DMAP, and PNP-Ni in DMF to obtain a reaction solution, stirring the reaction solution at room temperature for 12 hours, and then transferring it to a dialysis bag, dialyzing it in DMF for 24 hours, changing DMF once, and then dialyzing it in deionized water for 24 hours, changing the water twice, and freeze-drying to obtain a green solid PEG-pArg-pLys-Ni.
9. The method for preparing the nanoformulation according to claim 1, characterized in that: The steps include: The polymer PEG-pArg-pLys-Ni and silybin are dispersed in an organic solvent by a thin film hydration method, the organic solvent is removed by rotary evaporation to form a thin film, ultrapure water is added and ultrasonic dispersion is performed to obtain micelles, the micelles are mixed and adsorbed with gemcitabine monophosphate, and then mixed with hyaluronic acid for coating, and after coating, the unencapsulated free drug is removed by dialysis to obtain a nano preparation; Preferably, the mass ratio of PEG-pArg-pLys-Ni to silybin, gemcitabine monophosphate and hyaluronic acid is 8:1:8:4; the organic solvent is DMF; the mass ratio of ultrapure water to PEG-pArg-pLys-Ni is 2000:1; the ultrasonic dispersion time is 2h; the mixing time of micelles and gemcitabine monophosphate is 1h; and the hyaluronic acid coating time is 2h.
10. Use of the nanoformulation according to claim 1 in the preparation of anti-pancreatic cancer drugs.
Citation Information
Patent Citations
Hypoxia response drug delivery micelle adaptive to pancreatic cancer microenvironment and preparation method of hypoxia response drug delivery micelle
CN116509801A
